In contrast, sgp130 fusion proteins, such as olamkicept, have been reported to selectively inhibit trans-signaling, and have shown promising results in clinical trials for rheumatoid arthritis and inflammatory bowel diseases (Jones and Jenkins, 2018; Rose-John et al., 2023). Here, IL6ST is linked to inflammatory bowel disease.